NCT01178151

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome

Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this pilot study the investigators will treat all patients known with Peutz-Jeghers syndrome (PJS) who are diagnosed with advanced malignancies with everolimus 10mg daily until disease progression. Most patients with PJS have an inherited LKB1 mutation leading to aberrant m-TOR activity. Their risk to develop malignancies or intestinal polyps is probably related to this constitutive mTOR signaling. The hypothesis is that mTOR inhibition is an effective anticancer treatment in PJS patients with advanced malignancies.

Conditions

• Peutz-Jeghers Syndrome
• Neoplastic Processes
• Neoplasm Metastasis

Interventions

Type	Name	Description
DRUG	Everolimus	10mg daily orally

Timeline

• Start date: 2010-10-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2010-08-10
• Last updated: 2015-04-22

Locations

2 sites across 1 country: Netherlands